Study of Astaxanthin Supplementation for 12 Weeks in Women with Polycystic Ovary Syndrome Assessing Symptoms and Heart-Metabolic Health

What this Trial Is About

This research aims to evaluate the effects of 12 weeks of daily 10 mg astaxanthin ASX supplementation on insulin sensitivity, lipid profile, oxidative stress marker Malondialdehyde MDA, severity of hirsutism, and depression in women diagnosed with Polycystic Ovary Syndrome PCOS. PCOS is a common hormonal disorder in women of reproductive age, associated with metabolic dysfunction, infertility, and psychological issues. The study is a randomized, double-blind, placebo-controlled trial conducted in Isfahan, Iran, focusing on women with a BMI between 25 and 35 kgm2. Participants will be randomly assigned to receive either ASX supplements or a placebo capsule daily for 12 weeks. The ASX supplement is produced by Zyest Technology Tarawat Zendig institute and matched by placebo in appearance. Participants will be monitored every two weeks for supplement adherence, and they will be instructed to maintain their usual diet and physical activity levels throughout the study. The trial includes baseline and post-intervention assessments, including blood sampling and questionnaires. During the study, participants will undergo evaluations of anthropometric measurements, dietary intake, physical activity using the International Physical Activity Questionnaire, blood pressure, and biochemical markers such as lipid profile and insulin resistance. The severity of hirsutism will be assessed visually using the modified Ferriman-Gallwey scoring method. Blood samples will be collected at baseline and after 12 weeks for laboratory analysis. Researchers will monitor adherence closely and use several outcome measures to assess the impact of ASX supplementation over the study period.

The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Polycystic Ovary Syndrome